Characterizing patients with rare mucormycosis infections using real-world data

Zhang, Yayue; Sung, Amy; Rubinstein, E; Benigno, Michael; Chambers, Richard; Patino, Nataly; Aram, Jalal A

doi:10.1186/s12879-022-07115-w

Cited by 4 publications

(4 citation statements)

References 31 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even though the majority of Middle Eastern nations use electronic health records, there are limitations on updating the database to include data on laboratory markers and medication intake in order to maximize IFI management. Recently, the United States implemented Optum®, a data collection strategy, to gather anonymous data on invasive mucormycosis [69]. The Middle East could benefit from the development of these prediction models in order to collect information on the different types of IFIs, including the causative bacteria, AFT used, and patient outcomes.…”

Section: Management Challengesmentioning

confidence: 99%

Management of the fungal infections and challenges associated with it

Gayke,

Moazzam

2024

JIPBS

View full text Add to dashboard Cite

Fungal infections are becoming more common at an alarming rate, which poses a significant challenge to medical experts. This growth is directly linked to the rise in the number of people with impaired immune systems as a result of modifications to medical practice, including the use of immunosuppressive medications and intense chemotherapy. HIV and other illnesses that impair immunity have also had a role in this issue. Mucous membranes, keratinous tissues, and the skin are all impacted by superficial and subcutaneous fungal infections. This class includes some of the most common skin conditions that impact millions of people globally. They can have crippling consequences on a person's quality of life and, in certain cases, spread to other people or become invasive, even though they are rarely life-threatening. Fungal pathogens employ several tactics to compromise the immune system of the host and escalate infections. The range of antifungal drugs available is used to treat a number of superficial and systemic diseases. The well-established evidence of fungal resistance to most antifungal medicines complicates antifungal therapy and makes disease control challenging. Fungal resistance is caused by a range of genetic alterations, physiological alterations, and selection in the presence of antifungal drugs. The lack of a wide range of antifungal drugs, resistance building, and biofilm-conferred resistance are the main reasons for the need for novel therapeutics and other approaches to enhance treatment outcomes against mycoses.

show abstract

Section: Management Challengesmentioning

confidence: 99%

Management of the fungal infections and challenges associated with it

Gayke,

Moazzam

2024

JIPBS

View full text Add to dashboard Cite

show abstract

“…From 2001 to 2006, the Transplant-Associated Infection Surveillance Network (TRANSNET) in America reported 44 IM (0.3%) of 15,820 HSCT patients [7]. A multicenter, retrospective study conducted in America found that 1133 of 962,428 HMs patients suffered from IM (0.12%) between 2007 and 2019 [8]. From 2007 to 2017, a survey of the Children's Cancer Hospital in Egypt found 45 cases of proven IM among 13,735 hospitalized children (0.33%) who suffered from tumors [9].…”

Section: Epidemiology and Risk Factorsmentioning

confidence: 99%

Clinical Features and Treatment Progress of Invasive Mucormycosis in Patients with Hematological Malignancies

Yang

Zhang

Feng

2023

JoF

View full text Add to dashboard Cite

The incidence rate of invasive mucormycosis (IM) in patients with hematological malignancies (HMs) is increasing year by year, ranging from 0.07% to 4.29%, and the mortality rate is mostly higher than 50%. With the ongoing pandemic of COVID-19, COVID-19-associated mucormycosis (CAM) also became a global health threat. Patients with high risk factors such as active HMs, relapsed/refractory leukemia, prolonged neutropenia may still develop breakthrough mucormycosis (BT-MCR) even under the prophylaxis of Mucorales-active antifungals, and such patients often have higher mortality. Rhizopus spp. is the most common genus associated with IM, followed by Mucor spp. and Lichtheimia spp. Pulmonary mucormycosis (PM) is the most common form of IM in patients with HMs, followed by rhino-orbital-cerebral mucormycosis (ROCM) and disseminated mucormycosis. The prognosis of IM patients with neutrophil recovery, localized IM and receiving early combined medical–surgical therapy is usually better. As for management of the disease, risk factors should be eliminated firstly. Liposome amphotericin B (L-AmB) combined with surgery is the initial treatment scheme of IM. Those who are intolerant to L-AmB can choose intravenous formulations or tablets of isavuconazole or posaconazole. Patients who are refractory to monotherapy can turn to combined antifungals therapy.

show abstract

“…While electronic health records are used in most Middle Eastern countries, updating the database to include information on laboratory indicators and drug usage to optimize IFI management is limited. Recently, a data acquisition model called Optum® has been implemented in the US to collate unidentified data on invasive mucormycosis [ 46 ]. The development of such prediction models can be useful in the Middle East region to collate data on diverse types of IFIs, including causal pathogens, AFT used, and patient outcomes.…”

Section: Reviewmentioning

confidence: 99%

Challenges in the Management of Invasive Fungal Infections in the Middle East: Expert Opinion to Optimize Management Using a Multidisciplinary Approach

AlMaghrabi,

Al-Musawi,

Albaksami

et al. 2023

Cureus

View full text Add to dashboard Cite

Invasive fungal infection (IFI) is a significant global healthcare concern among critically ill and immunocompromised patients. In Middle Eastern countries, IFI has been steadily increasing among hospitalized patients in the past two decades. Diagnosis of IFI at an early stage is crucial for efficient management. Invasive fungal infection management is complex and requires the involvement of physicians from different specialties. There are several challenges associated with IFI management in the countries in the Middle East. This review aims to understand the key challenges associated with IFI management in the Middle East, encompassing epidemiology, diagnosis, therapeutic options, and optimizing a multidisciplinary approach. In addition, this review aims to incorporate expert opinions from multidisciplinary fields for optimizing IFI management in different Middle Eastern countries by addressing key decision points throughout the patient’s journey. Lack of epidemiological data on fungal infections, slow and poorly sensitive conventional culture-based diagnostic tests, limited availability of biomarker testing, lack of awareness of clinical symptoms of the disease, limited knowledge on fungal infections, lack of local practice guidelines, and complicated disease management are the major challenges associated with IFI diagnosis and management in the Middle Eastern countries. Implementation of a multidisciplinary approach, antifungal stewardship, improved knowledge of fungal infections, the use of rapid diagnostic tests, and enhanced epidemiological research are warranted to lower the IFI burden in the Middle East.

show abstract

Characterizing patients with rare mucormycosis infections using real-world data

Cited by 4 publications

References 31 publications

Management of the fungal infections and challenges associated with it

Management of the fungal infections and challenges associated with it

Clinical Features and Treatment Progress of Invasive Mucormycosis in Patients with Hematological Malignancies

Challenges in the Management of Invasive Fungal Infections in the Middle East: Expert Opinion to Optimize Management Using a Multidisciplinary Approach

Contact Info

Product

Resources

About